Through its front door service, MedCity has supported over 200 new customers in 2017/18 – including international companies and academics – to grow their innovations in the greater south east of England.

Companies, academics and investors, were supported by the region’s life sciences cluster organisation to sell into the NHS, develop international research partnerships, source appropriate lab space, and connect with its angel investing programme.

England’s greater south east has four of the world’s top ten universities; over 3400 life sciences companies, including 19 of the top 20 global pharmaceutical companies; and leading medical research institutes including The Francis Crick Institute, Wellcome Trust and the Medical Research Council.

The organisation, supported by the Mayor of London, the London Academic Health Science Centres, and research institutes and life sciences organisations, has boosted economic growth in the region. In 2017/18, MedCity has:

• Supported over 200 new customers through its front door service, and 800 since inception, to help set up in the region, understand the healthcare systems, and connect to the right people
• Helped SMEs to access over £7m investment through its Angels in MedCity programme, as part of its aim to encourage entrepreneurship
• Directly led to £13.3m in additional life sciences jobs for the region
• Organised, spoken at, or helped deliver over 70 life sciences and healthcare events across the UK and globally, to promote the region
• Organised a 60-strong life sciences delegation to Japan and Korea; for life sciences partnering convention BioJapan, a symposium in Tokyo, and company meetings in Korea
• Provided advice for new infrastructure, including the British Library redevelopment, Imperial College White City expansion, and the Knowledge Quarter development.
• Connected 15 companies with academics at four leading London universities through its Collaborate to Innovate programme.

Sarah Haywood, CEO, MedCity said:

“We have seen exciting new developments across the greater south east of England this year, with the Cell and Gene Therapy Catapult’s new £60m manufacturing centre; continued development of the Imperial White City Cluster; progress on Oxford’s BioEscalator; and the AstraZeneca HQ in Cambridge nearing completion.

“Over the last 12 months we have helped companies to understand and set up in the region, been a part of high-profile events and delegations, and built on our relationships with global companies – all contributing to ensuring the region is positioned as a world-leading life sciences hub.”

“Equally, the regional clusters have been recognised as making a significant contribution to the sector and we continue to work with partners around the UK to deliver a front door to the UK’s capability. As we enter our fifth year, alongside our core work, we will double our efforts to work closer with our partners to attract greater talent, funding and investment opportunities into the region; and ensure we get a good deal for science post-Brexit.”

Rajesh Agrawal, Deputy Mayor of London for Business, said:

“London led Europe for life sciences investment in 2017 with companies raising £909m investment, and it’s no surprise to see that 63% of the UK’s life sciences investment landed in ‘The Golden Triangle’ of London, Oxford and Cambridge. The region is leading the way for scientific innovation and MedCity is crucial in supporting international businesses, academics and investors to navigate the complex ecosystem to develop collaborations, support commercialisation, and importantly, improve patient health.”


  • Please see the annual report here: here
  • MedCity is funded and supported by the Higher Education Funding Council for England (HEFCE), the Greater London Authority (GLA), and the European Regional Development Fund (ERDF).